Harbor Investment Advisory’s Blueprint Medicines BPMC Stock Holding History

Harbor Investment Advisory’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,232	Closed	-$77.9K	–	1205
2023 Q2	$77.9K	Buy	1,232 +119	+11%	+$6.47K	0.01%	570
2023 Q1	$50.1K	Hold	1,113	–	–	0.01%	701
2022 Q4	$48.8K	Sell	1,113 -2,373	-68%	-$114K	0.01%	697
2022 Q3	$230K	Hold	3,486	–	–	0.04%	307
2022 Q2	$176K	Hold	3,486	–	–	0.03%	359
2022 Q1	$223K	Hold	3,486	–	–	0.03%	351
2021 Q4	$373K	Hold	3,486	–	–	0.05%	259
2021 Q3	$358K	Hold	3,486	–	–	0.05%	270
2021 Q2	$307K	Buy	3,486 +186	+6%	+$17K	0.04%	291
2021 Q1	$321K	Buy	3,300 +104	+3%	+$10.4K	0.05%	265
2020 Q4	$358K	Sell	3,196 -1,899	-37%	-$200K	0.06%	228
2020 Q3	$472K	Buy	5,095 +1,080	+27%	+$83.2K	0.09%	171
2020 Q2	$313K	Buy	+4,015	New	+$272K	0.07%	200

Other funds holding BPMC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Harbor Investment Advisory's BPMC Position: Q3 2023 in Review

Harbor Investment Advisory sold out of Blueprint Medicines (BPMC) in Q3 2023, closing a stake of 1,232 shares — an estimated $77.9K sold.

Harbor Investment Advisory first reported a position in BPMC in Q2 2020 and held it in 13 quarters. The position peaked at $472K in Q3 2020. 220 funds tracked by Wall St. Rank hold BPMC as of Q3 2023.

Harbor Investment Advisory reported no remaining Blueprint Medicines position as of Q3 2023 after selling out during the quarter.
Harbor Investment Advisory sold 1,232 Blueprint Medicines shares in Q3 2023, an estimated $77.9K.
Harbor Investment Advisory first reported a position in Blueprint Medicines in Q2 2020 and held it in 13 quarters.
Harbor Investment Advisory's Blueprint Medicines position peaked at $472K in Q3 2020.
220 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2023.

Based on Harbor Investment Advisory's 13F filing for Q3 2023, filed 13 Oct 2023.